Brought to you by 
Celimmune gets license to Amgen's Phase II celiac candidate; Amgen takes back rights
05 Nov 2018
Executive Summary
Amgen Inc. licensed newly formed Celimmune LLC exclusive global rights (excluding Japan) to develop, manufacture, and commercialize the Phase II monoclonal antibody AMG714 for celiac disease.
Deal Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
- Specialty Pharmaceuticals
Deal Status
- Terminated
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Celimmune gets license to Amgen's Phase II celiac candidate; Amgen takes back rights
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice